Next generation chemotherapy: improved treatment for more patients

Hanover, md, june 14, 2023 (globe newswire) -- processa pharmaceuticals, inc. (nasdaq: pcsa) (“processa” or the “company”), a clinical-stage pharmaceutical company now focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces that ceo david young, pharm.d., ph.d. will present at the medinvest oncology investor conference being held on june 21-22, 2023 in boston, ma.
PCSA Ratings Summary
PCSA Quant Ranking